| Drug Name |
Chloroquine phosphate |
| Drug ID |
BADD_D00441 |
| Description |
Chloroquine is an aminoquinolone derivative first developed in the 1940s for the treatment of malaria.[A191655] It was the drug of choice to treat malaria until the development of newer antimalarials such as [pyrimethamine], [artemisinin], and [mefloquine].[A191787] Chloroquine and its derivative [hydroxychloroquine] have since been repurposed for the treatment of a number of other conditions including HIV, systemic lupus erythematosus, and rheumatoid arthritis.[A192432]
**The FDA emergency use authorization for [hydroxychloroquine] and chloroquine in the treatment of COVID-19 was revoked on 15 June 2020.[L14312]**
Chloroquine was granted FDA Approval on 31 October 1949.[L12054] |
| Indications and Usage |
For the suppressive treatment and for acute attacks of malaria due to P. vivax, P.malariae, P. ovale, and susceptible strains of P. falciparum, Second-line agent in treatment of Rheumatoid Arthritis |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
P01BA01 |
| DrugBank ID |
DB00608
|
| KEGG ID |
D02125
|
| MeSH ID |
C023676
|
| PubChem ID |
64927
|
| TTD Drug ID |
D09EGZ
|
| NDC Product Code |
68022-0265; 64980-178; 57451-1116; 68022-0264; 63850-8080; 64980-177; 76385-142; 49452-2408; 50090-4967; 68022-7057; 73377-028 |
| Synonyms |
chloroquine diphosphate | chingamin phosphate | N(4)-(7-chloro-4-quinolinyl)-N(1),N(1)-diethyl-1,4-pentanediamine, phosphate (1:2) | delagil | khingamin phosphate | unspecified phosphate of chloroquine diphosphate | arechin | chloroquine phosphate | Resochin | chloroquine diphosphate, (+-)-isomer | chloroquine diphosphate, (-)-isomer | chloroquine bis(dihydrogenphosphate) dihydrate | chloroquine diphosphate, (+)-isomer |
